In his new role, Mr. Isom will lead Alcami’s commercial strategy for laboratory services, deepen engagement with biotechnology and pharmaceutical partners, and support the continued expansion of Alcami’s standalone analytical offerings.
His appointment reflects Alcami’s ongoing commitment in delivering reliable solutions for clients increasingly complex biologic therapies.
Will brings a rare combination of scientific understanding, commercial leadership, and operational experience. His expertise will help strengthen client partnerships and accelerate growth across our analytical services and biologics business.
Said Katie Schlipp, President, Laboratory Services.
Mr. Isom brings more than two decades of experience in biologics development, quality control, commercial strategy, and operational leadership. His career includes leadership roles at Charles River Laboratories, where he advanced through multiple commercial and business development positions and later served as Site Director following the acquisition of Cognate BioServices. Most recently, he led Texcell’s global commercial organisation, overseeing commercial strategy for advanced therapy programs.
With Mr. Isom’s leadership, Alcami continues to enhance its commercial capabilities and reinforce its position as a trusted partner for biologics development, analytical testing, and manufacturing.
